Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with Dr. Virginia Kaklamani - Professor of Medicine - Leader of Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center.
#emerald #oncology #fda #elacestrant #2023 #oncology #oncbrothers
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Contact us at info@oncbrothers.com
